Eqis Capital Management Inc. purchased a new position in Amsurg Corp. (NASDAQ:AMSG) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,946 shares of the company’s stock, valued at approximately $332,000.
A number of other institutional investors have also bought and sold shares of AMSG. Emerald Acquisition Ltd. purchased a new position in shares of Amsurg Corp. during the second quarter worth approximately $106,000. Smith Asset Management Group LP increased its position in shares of Amsurg Corp. by 8,500.0% in the second quarter. Smith Asset Management Group LP now owns 1,720 shares of the company’s stock worth $133,000 after buying an additional 1,700 shares during the period. Checchi Capital Advisers LLC purchased a new position in shares of Amsurg Corp. during the second quarter worth approximately $157,000. Advisor Group Inc. purchased a new position in shares of Amsurg Corp. during the second quarter worth approximately $202,000. Finally, World Asset Management Inc purchased a new position in shares of Amsurg Corp. during the second quarter worth approximately $204,000. Hedge funds and other institutional investors own 98.67% of the company’s stock.
Shares of Amsurg Corp. (NASDAQ:AMSG) traded up 0.71% during midday trading on Friday, reaching $66.22. 296,468 shares of the company traded hands. The company’s 50 day moving average is $64.34 and its 200-day moving average is $70.20. The stock has a market capitalization of $3.56 billion, a price-to-earnings ratio of 20.44 and a beta of 0.67. Amsurg Corp. has a 12 month low of $57.32 and a 12 month high of $86.17.
Amsurg Corp. (NASDAQ:AMSG) last released its quarterly earnings results on Tuesday, November 1st. The company reported $1.13 earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of $1.13. Amsurg Corp. had a net margin of 6.06% and a return on equity of 8.05%. The company had revenue of $822.20 million for the quarter, compared to analysts’ expectations of $770.29 million. During the same period last year, the company earned $1.03 EPS. The firm’s revenue for the quarter was up 26.5% compared to the same quarter last year. Equities research analysts forecast that Amsurg Corp. will post $4.31 earnings per share for the current fiscal year.
AMSG has been the topic of a number of analyst reports. Zacks Investment Research downgraded shares of Amsurg Corp. from a “buy” rating to a “hold” rating in a research note on Friday, August 5th. Citigroup Inc. initiated coverage on shares of Amsurg Corp. in a research note on Monday, September 26th. They set a “buy” rating and a $79.00 target price on the stock. KeyCorp reaffirmed a “positive” rating and set a $87.00 target price on shares of Amsurg Corp. in a research note on Tuesday, October 4th. Wells Fargo & Co. raised shares of Amsurg Corp. from a “market perform” rating to an “outperform” rating in a research note on Wednesday, November 2nd. They noted that the move was a valuation call. Finally, Cantor Fitzgerald set a $90.00 price target on shares of Amsurg Corp. and gave the company a “buy” rating in a research note on Wednesday, November 2nd. Three investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $89.45.
Amsurg Corp. Company Profile
AmSurg Corp. is a surgical center and physician services company. The Company is an owner and operator of ambulatory surgery centers (ASCs) in the United States. The Company is also a provider of outsourced physician services in the areas of anesthesiology, children’s services, emergency medicine and radiology.